Shares of Regeneron Inc and Sanofi SA slid on Monday after late-stage trial data for their asthma drug, dupilumab, fell short of investor... ...http://feeds.reuters.com/~r/reuters/INhealth/~3/ajDCb0bkIP0/regeneron-sanofi-asthma-drug-data-fails-to-excite-investors-idINKCN1BM0L8
Launches Combiflam ICYHOT, pain relief topical in India ...http://www.business-standard.com/article/news-cm/sanofi-india-expands-its-consumer-healthcare-portfolio-117091100968_1.html
The Supreme Court on Thursday upheld the Competition Appellate Tribunal's (Compat's) order quashing a penalty of Rs 64 crore imposed by the... ...http://www.business-standard.com/article/current-affairs/sc-rejects-cci-order-against-gsk-sanofi-117081001233_1.html
(Reuters) - Regeneron Pharmaceuticals Inc reported a much better-than-expected quarterly profit on strong demand for its flagship Eylea drug and... ...http://feeds.reuters.com/~r/reuters/INhealth/~3/UApW1T4Y0VQ/us-regeneron-results-idINKBN1AJ1EV
GlaxoSmithKline is swimming against the tide by getting out of treatments for rare diseases at a time when rivals like Sanofi and Shire see the... ...http://feeds.reuters.com/~r/reuters/INhealth/~3/SOy_oPvMtuE/us-gsk-results-rare-diseases-idINKBN1AB2EE
Radisson Blu Hotel New Delhi Paschim...